Nurix Therapeutics Will Present Preclinical Data From NX-5948, Currently In Phase 1b For B-Cell Malignancies And In IND-Enabling Studies For Autoimmune Disease, And GS-6791/NX-0479 In Collaboration With Gilead Sciences And Also In IND-enabling Studies, At The American College Of Rheumatology Convergence 2024
Portfolio Pulse from Benzinga Newsdesk
Nurix Therapeutics is set to present preclinical data on NX-5948 and GS-6791/NX-0479 at the American College of Rheumatology Convergence 2024. NX-5948 is in Phase 1b for B-cell malignancies and IND-enabling studies for autoimmune diseases. GS-6791/NX-0479 is developed in collaboration with Gilead Sciences.
October 09, 2024 | 11:24 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Gilead Sciences is collaborating with Nurix on GS-6791/NX-0479, which will be presented at ACR Convergence 2024. This collaboration may enhance Gilead's pipeline in autoimmune diseases.
The collaboration with Nurix on GS-6791/NX-0479 and its presentation at a major conference could enhance Gilead's pipeline, potentially leading to positive investor sentiment.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 70
POSITIVE IMPACT
Nurix Therapeutics will present preclinical data on NX-5948 and GS-6791/NX-0479, indicating progress in their drug development pipeline. This could positively impact investor sentiment.
The presentation of preclinical data at a major conference highlights Nurix's progress in drug development, which is likely to boost investor confidence and potentially lead to positive stock movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90